Neuland Laboratories Ltd
NSE:NEULANDLAB
Neuland Laboratories Ltd
Change in Working Capital
Neuland Laboratories Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
Change in Working Capital
-₹1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Change in Working Capital
-₹55.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Change in Working Capital
-₹23.7B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Change in Working Capital
-₹9.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Change in Working Capital
-₹1.1B
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Change in Working Capital
-₹4.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.
See Also
What is Neuland Laboratories Ltd's Change in Working Capital?
Change in Working Capital
-1.7B
INR
Based on the financial report for Dec 31, 2024, Neuland Laboratories Ltd's Change in Working Capital amounts to -1.7B INR.
What is Neuland Laboratories Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-62%
Over the last year, the Change in Working Capital growth was -62%.
You don't have any saved screeners yet